论文部分内容阅读
目的观察抗柯萨奇B病毒性心肌炎胶囊(KCoxBJN)复方新制剂长期给药对大鼠血液系统是否产生影响,以为临床安全用药提供实验依据。方法将Wistar大鼠随机分高、中、低三个剂量组和对照组,每组雌雄各20只,分别为KCoxB-JN复方新制剂1.36,0.68和0.34 g.kg-1.d-1灌胃给药(相当于生药量13.6,6.8和3.4 g.kg-1.d-1),为人用有效剂量的40,20和10倍;对照组每天灌胃蒸馏水。连续灌胃给药90天及停药2周后,各组分别随机取雌雄各10只,尾静脉取血,测定血液学指标:包括白细胞,单核细胞,淋巴细胞,中性粒细胞,红细胞,血红蛋白,血小板等。结果复方新制剂连续给药90天及停药2周后对大鼠血液学指标无明显影响,给药组各指标与对照组比较,均无明显差异。结论 KCoxB-JN复方新制剂长期给药及停药恢复期对大鼠血液系统没有造成明显的影响。
Objective To observe whether the long-term administration of the compound new preparation of Coxsackie B virus myocarditis capsule (KCoxBJN) affects the blood system of the rats and provide an experimental basis for clinical safe medication. Methods Wistar rats were randomly divided into three groups: high, middle and low dose groups and control group, with 20 male and female in each group, which were respectively 1.36, 0.68 and 0.34 g.kg-1.d-1 of KCoxB-JN Gastric administration (equivalent to 13.6, 6.8 and 3.4 g.kg-1.d-1 for crude drug production) was 40, 20 and 10 times the effective dose for humans, while the control group was given distilled water daily. After continuous oral administration for 90 days and withdrawal for 2 weeks, 10 female and 10 female rats were randomly selected from each group. Blood was collected from tail vein to determine hematological indexes including white blood cells, monocytes, lymphocytes, neutrophils, erythrocytes , Hemoglobin, platelets and so on. RESULTS: The new preparation of compound prescription had no significant effect on the hematological indexes of rats for 90 days and two weeks after withdrawal. There was no significant difference between the two groups in the indexes of the administration group and the control group. Conclusion The long-term administration of KCoxB-JN compound and the recovery period of drug withdrawal have no obvious effect on the blood system in rats.